HVTN 505
Status:Stopped Early
Phase:IIb
Principal Investigator(s):Scott Hammer, Columbia University
Objective:To determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
last updated March 27, 2021
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionParticipants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28, and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168.
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionParticipants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168.
Mode of DeliveryIntramuscular
ARMsPlacebo Comparator
Official Code:
NCT00865566
Trial Sponsors:
HVTN, NIAID
Start Date
End Date
June 1, 2009
August 2, 2017
Enrollment:2,504
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Gay and Bisexual Men Who Have Sex with Men